References
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
- Chen WQ, Zeng HM, Zheng RS, Zhang SW, He J. Cancer incidence and mortality in china, 2007. Chin J Cancer Res. 2012;24(1):1–8.
- Chade DC, Shariat SF, Dalbagni G. Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. Int Braz J Urol. 2009;35(6):640–50.
- Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52:1123–29.
- Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int. 2012;109(4):496–505.
- Yanqun Na. The CUA guideline for urological disease.[M]. Beijing: People's Health Publishing House; 2007:95–96.
- Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, On behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual, 3rd edn. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
- Homma Y, Yoshida M, Yamanishi T Gotoh M. Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int J Urol. 2008;15(9):816–20.
- Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, et al. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013 Mar 29. doi: 10·1016/j.juro.2013·03·097. [Epub ahead of print].
- Singer S, Ziegler C, Schwalenberg T Hinz A, Götze H, Schulte T. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer. 2013;21(5):1383–93.
- Metcalfe M, Estey E, Jacobsen NE, Voaklander D, Fairey AS. Association between urinary diversion and quality of life after radical cystectomy. Can J Urol. 2013;20(1):6626–31.
- Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol. 2012;62(5):797–802.
- Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, et al. Phase I trial of intravesical recombinant adenovirus-mediated interferon-α2b formulated in Syn3 for BCG failures in non-muscle-invasive bladder cancer. J Urol. 2013 Mar 15. doi:10·1016/j.juro.2013·03·030. [Epub ahead of print].
- Abbona A, Morabito F, Rossi R, Billia M, Liberale F, Ferrando U. Quality of life in patients undergone oncopreventive intravesical treatment for superficial bladder cancer. Arch Ital Urol Androl. 2007;79(4):143–6.
- Bohle A, Balck F, von Weitersheim J Jocham D. The quality of life during intravesical bacillus Calmette-Guérin therapy. J Urol. 1996;155(4):1221–6.
- Lamm DL, Blumenstein BA, Crawford ED Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205–9.
- Chen SY, DU LD, Zhang YH. Pilot study of intravesical instillation of two new generation anthracycline antibiotics in prevention of superficial bladder cancer recurrence. Chin Med J (Engl). 2010;123(23):3422–6.